News

HPV testing best predicts cervical neoplasia risk

Publish date: April 2, 2013

 

AT THE ANNUAL MEETING ON WOMEN'S CANCER

Dr. Wright disclosed that he is a consultant for Roche Molecular Systems, BD Diagnostics, Cepheid, and Hologic. The trial was sponsored by Roche Molecular Systems.

Pages

Recommended Reading

Pregnancies after vasculitis diagnosis are at risk
MDedge Internal Medicine
Intra-amniotic debris predicts early preterm birth in nulliparas with short cervix
MDedge Internal Medicine
FDA panel rejects SSRI's approval as a hot flash treatment
MDedge Internal Medicine
Recommendations for gestational diabetes mellitus screening remain unchanged
MDedge Internal Medicine
Previous abortion no longer a risk factor for preterm birth
MDedge Internal Medicine
Trial of labor after C-section uncommon, but often successful
MDedge Internal Medicine
Breast cancer: Cardiac risk increases with radiation dose to heart
MDedge Internal Medicine
Being postmenopausal doubles hepatic steatosis risk
MDedge Internal Medicine
Placental abruption a strong risk factor for long-term CVD death
MDedge Internal Medicine
Skin capillary density drop reliably predicts preeclampsia
MDedge Internal Medicine